Mutation-based, short-term “neoadjuvant” treatment allows resectability in stage IVB and C anaplastic thyroid cancer

INTRODUCTION: Few available data indicate that a mutation-based “neoadjuvant” therapy in advanced anaplastic thyroid carcinoma (ATC) might convert an initially unresectable primary tumor to resectable and optimize local tumor control. We evaluated a preoperative short-term “neoadjuvant” therapy with...

Descripción completa

Detalles Bibliográficos
Autores principales: Maurer, Elisabeth, Eilsberger, F., Wächter, S., Riera Knorrenschild, J., Pehl, A., Holzer, K., Neubauer, A., Luster, M., Bartsch, D. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899736/
https://www.ncbi.nlm.nih.gov/pubmed/36637521
http://dx.doi.org/10.1007/s00405-023-07827-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899736/
https://www.ncbi.nlm.nih.gov/pubmed/36637521
http://dx.doi.org/10.1007/s00405-023-07827-y

Ejemplares similares